Trial Profile
A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Dec 2021 Status changed from active, no longer recruiting to completed.
- 22 Dec 2021 Status changed from active, no longer recruiting to completed.
- 11 Nov 2020 This trial has been completed in Ireland as per European Clinical Trials Database record, global end of the trial (2020-07-15 ).